Atomoxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
Open accessAbstract
Objective To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine.Method Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks with placebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were diagnosed with comorbid ODD and 61% were not. Treatment-group differences and differences between patients with and without comorbid ODD were examined post hoc for changes on the Attention-Deficit/Hyperactivity Disorder Rating Scale IV-Parent version, investigator-administered and -scored; Conners' Parent Rating Scale-Revised Short Form; Clinical Global Impressions Severity of ADHD Scale; and the parent-rated Child Health Questionnaire.Results Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures. Treatment response was similar in youths with and without ODD, except that the comorbid group showed improvement compared with placebo at 1.8 mg/kg/day but not 1.2 mg/kg/day. In contrast, youths without ODD showed improvement at 1.2 mg/kg/day and no incremental benefit at 1.8 mg/kg/day.Conclusions Atomoxetine treatment improves ADHD and ODD symptoms in youths with ADHD and ODD, although the comorbid group may require higher doses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some reports have documented the efficacy of stimulants, extended-release guanfacine and atomoxetine for the treatment of co-morbid oppositional defiant disorder symptoms.
“Some reports have docu mented the efficacy of stimulants 181 , extended-release guanfacine 182 and atomoxetine 183 for the treatment of co-morbid o ppositional defiant d isorder symptoms.”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [183]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,588 · see citing works
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,406 · see citing works
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 5,930 · see citing works
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372 · see citing works
(1998) · Cited by 2,026 · see citing works
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738 · see citing works
Davis, H. S. (1966) · JAMA · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719 · see citing works
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · see citing works
Conners' rating scales-revised : technical manual
Conners, C. K. (1997) · Medical Entomology and Zoology · Cited by 1,014 · see citing works
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666 · see citing works
Self-citation(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1088 · Cited by 652 · see citing works
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · see citing works
Self-citationJensen, P. N., Arnold, L. E., Richters, J., Severe, J. B., Vereen, D. R., Vitiello, B., Schiller, E., Hinshaw, S. P., Elliott, G. R., Conners, C., et al. (1999) · Institutional Research Information System University of Turin (University of Turin) · Cited by 432 · see citing works
Self-citationLandgraf, J. M., Maunsell, E., Speechley, K. N., Bullinger, M., Campbell, S., Abetz, L. N., & Ware, J. E. (1998) · Quality of Life Research · doi:10.1023/a:1008810004694 · Cited by 388 · see citing works
Bupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity
CONNERS, C. K., CASAT, C. D., GUALTIERI, C. T., WELLER, E., READER, M., REISS, A., WELLER, R. A., KHAYRALLAH, M., & ASCHER, J. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00018 · Cited by 342 · see citing works
Effectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorder
Spencer, T., Biederman, J., Wilens, T. E., Prince, J., Hatch, M., Jones, J. T., CRAWFORD, M. H., Faraone, S. V., & Seidman, L. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.693 · Cited by 336 · see citing works
Self-citationCONNOR, D. F., GLATT, S. J., LOPEZ, I. D., JACKSON, D., & MELLONI, R. H. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200203000-00004 · Cited by 333 · see citing works
A Double-Blind Placebo Controlled Study of Desipramine in the Treatment of ADD: I. Efficacy
Biederman, J., Baldessarini, R. J., WRIGHT, V., Knee, D., & Harmatz, J. S. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198909000-00022 · Cited by 310 · see citing works
Self-citationGreene, R. W., Biederman, J., Zerwas, S. C., Monuteaux, M. C., Goring, J. C., & Faraone, S. V. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1214 · Cited by 310 · see citing works
Self-citationAn Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder
Hunt, R. D., Arnsten, A. F. T., & Asbell, M. D. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199501000-00013 · Cited by 308 · see citing works
Medication treatment strategies in the MTA Study: relevance to clinicians and researchers
GREENHILL, L. L., ABIKOFF, H. B., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., ELLIOTT, G., HECHTMAN, L., HINSHAW, S. P., HOZA, B., JENSEN, P. S., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00017 · Cited by 297 · see citing works
Self-citationBiederman, J., Faraone, S. V., & Monuteaux, M. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1556 · Cited by 291 · see citing works
Self-citationA Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272 · see citing works
Self-citationWilens, T. E. (2004) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00113-8 · Cited by 264 · see citing works
August, G. J., Realmuto, G. M., MacDonald, A. W., Nugent, S. M., & Crosby, R. D. (1996) · Research on Child and Adolescent Psychopathology · doi:10.1007/bf01670101 · Cited by 237 · see citing works
Impact of Comorbid Oppositional or Conduct Problems on Attention-Deficit Hyperactivity Disorder
KUHNE, M., SCHACHAR, R., & TANNOCK, R. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199712000-00020 · Cited by 209 · see citing works
Connor, D. F., Barkley, R. A., & Davis, H. T. (2000) · Clinical Pediatrics · doi:10.1177/000992280003900102 · Cited by 203 · see citing works
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.
Wong, D. T., Threlkeld, P. G., Best, K. L., & Bymaster, F. P. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33153-8 · Cited by 194 · see citing works
Factors influencing elementary school teachers' ratings of ADHD and ODD behaviors
Stevens, J. H., & Quittner, A. L. (1998) · Journal of Clinical Child Psychology · doi:10.1207/s15374424jccp2704_4 · Cited by 118 · see citing works
Sawyer, M., Antoniou, G., Toogood, I. R. G., & Rice, M. S. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199712000-00022 · Cited by 116 · see citing works
Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polisner, D. A., & Bostic, J. Q. (2000) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/10445460050167304 · Cited by 95 · see citing works
Self-citationAssessment and Diagnosis of Attention-Deficit/Hyperactivity Disorder
Hechtman, L. T. (2000) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(18)30102-0 · Cited by 86 · see citing works
Nortriptyline in the Treatment of ADHD: A Chart Review of 58 Cases
Wilens, T. E., Biederman, J., Geist, D. E., Steingard, R. J., & Spencer, T. J. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199303000-00015 · Cited by 70 · see citing works
Self-citationRd, H., Minderaa, R. B., & Dj, C. (1986) · PubMed · Cited by 62 · see citing works
Daly, J. M., & Fritsch, S. L. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199501000-00014 · Cited by 61 · see citing works
Biederman, J., Baldessarini, R. J., WRIGHT, V., Keenan, K. E., & Faraone, S. V. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199301000-00028 · Cited by 57 · see citing works
Self-citationGehlert, D. R., Schober, D. A., Hemrick-Luecke, S. K., Krushinski, J. H., Howbert, J. J., Robertson, D. W., Fuller, R. W., & Wong, D. T. (1995) · Neurochemistry International · doi:10.1016/0197-0186(94)00113-9 · Cited by 37 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [1]1. Dr. Newcorn is an advisor for Celtech Pharmaceuticals, Eli Lilly and Company, Novartis Pharmaceuticals, and Ortho-McNeil Pharmaceuticals; he is a speaker for Eli Lilly and Company, Janssen Pharmaceutical, Novartis Pharmaceuticals, and Ortho-McNeil Phar- maceuticals; he receives grants from Eli Lilly and Company, Ortho Mc- Neil Pharmaceuticals, and Shire Pharmaceuticals; and he is a consultant for Eli Lilly and Company. Dr. Spencer is on the advisory boards of Eli Lilly and Company, GlaxoSmithKline, McNeil Pharmaceutical, No- vartis Pharmaceutical, Pfizer Pharmaceutical, and Shire Laboratories, Inc.; he is a speaker for Eli Lilly and Company, GlaxoSmithKline, McNeil Pharmaceutical, Novartis Pharmaceutical, Shire Laboratories, and Wyeth Ayerst; and he receives research support from Eli Lilly and Company, GlaxoSmithKline, McNeil Pharmaceutical, Novartis Phar- maceutical, Pfizer Pharmaceutical, and Shire Laboratories Inc. Dr. Biederman is on the advisory boards of CellTech, Cephalon Pharma- ceutical, Eli Lilly and Company, Janssen Pharmaceutical, Johnson & Johnson, McNeil Pharmaceutical, New River Pharmaceuticals, Novar- tis Pharmaceutical, Noven, Pfizer Pharmaceutical, Sanofi-Synthelabo, and Shire Laboratories Inc.; he is a speaker for Cephalon Pharmaceu- tical, Eli Lilly and Company, McNeil Pharmaceutical, Novartis Phar- maceutical, Pfizer Pharmaceutical, Shire Laboratories Inc., and Wyeth Ayerst; and he receives research support from Cephalon Pharmaceutical, Eli Lilly and Company, Janssen Pharmaceutical, Neurosearch Pharma- ceuticals, Pfizer Pharmaceutical, Shire Laboratories Inc., and the Stan- ley Medical Institute. Dr. Michelson and Ms. Milton are employees and stakeholders of Eli Lilly and Company. REFERENCES American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychi- atric Press
Cited by
Sorted by citations
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479 · see citing works
Self-citationThe quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516 · see citing works
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0549-0 · Cited by 375 · see citing works
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial
ARNOLD, L. E., AMAN, M. G., COOK, A. M., WITWER, A. N., HALL, K. L., THOMPSON, S., & RAMADAN, Y. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231976.28719.2a · Cited by 260 · see citing works
Connor, D. F., Steeber, J., & McBurnett, K. (2010) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181e121bd · Cited by 218 · see citing works
Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0840-x · Cited by 185 · see citing works
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166 · see citing works
Jonsson, U., Alaie, I., Löfgren Wilteus, A., Zander, E., Marschik, P. B., Coghill, D., & Bölte, S. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12645 · Cited by 164 · see citing works
Barkley, R. A., & Brown, T. E. (2008) · CNS Spectrums · doi:10.1017/s1092852900014036 · Cited by 163 · see citing works
Pliszka, S. R. (2007) · Neuropsychology Review · doi:10.1007/s11065-006-9017-3 · Cited by 158 · see citing works
Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120 · see citing works
Coghill, D. (2010) · CNS Drugs · doi:10.2165/11537450-000000000-00000 · Cited by 103 · see citing works
Bangs, M. E., Hazell, P., Danckaerts, M., Hoare, P., Coghill, D. R., Wehmeier, P. M., Williams, D. W., Moore, R. J., Levine, L., & for the Atomoxetine ADHD/ODD Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-1880 · Cited by 79 · see citing works
Svanborg, P., Thernlund, G., Gustafsson, P. A., Hägglöf, B., Poole, L., & Kadesjö, B. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-008-0725-5 · Cited by 71 · see citing works
Attention-Deficit/Hyperactivity Disorder and Early-Onset Substance Use Disorders
Wilson, J. J., & Levin, F. R. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.751 · Cited by 71 · see citing works
Dell'Agnello, G., Maschietto, D., Bravaccio, C., Calamoneri, F., Masi, G., Curatolo, P., Besana, D., Mancini, F., Rossi, A., Poole, L., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.07.008 · Cited by 54 · see citing works
Martenyi, F., Zavadenko, N. N., Jarkova, N. B., Yarosh, A. A., Soldatenkova, V. O., Bardenstein, L. M., Kozlova, I. A., Neznanov, N. G., Maslova, O. I., Petrukhin, A. S., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0042-7 · Cited by 36 · see citing works
Toward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33 · see citing works
Changes in Emotions Related to Medication Used to Treat ADHD. Part I: Literature Review
Manos, M. J., Brams, M., Childress, A. C., Findling, R. L., López, F. A., & Jensen, P. S. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710381230 · Cited by 28 · see citing works
Sinzig, J., & Lehmkuhl, G. (2007) · Psychopathology · doi:10.1159/000105531 · Cited by 14 · see citing works
Frölich, J., Lehmkuhl, G., & Döpfner, M. (2010) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917.a000002 · Cited by 5 · see citing works
- Authors
- Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 44
- Issue
- 3
- Pages
- 240-248
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W1967288147
- Cited by
- 174
- References
- 39
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 3 · 2017: 8 · 2016: 12 · 2015: 9 · 2014: 9 · 2013: 4 · 2012: 12
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Shire
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, oppositional defiant disorder, comorbidities, treatment response, dose-response relationship, children and adolescents, quality of life, ADHD Rating Scale
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Norepinephrine, Propylamines, Attention Deficit and Disruptive Behavior Disorders, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
